Mammalian Target of Rapamycin (Mtor) Inhibitors, Pipeline Insights, 2016
DelveInsight’s, “Mammalian target of rapamycin (mTOR) inhibitors -Pipeline Insights, 2016”, report provides comprehensive insights about pipeline drugs accross this mechanism of action. Key objective of the report is to establish the understanding for all the pipeline drugs that fall under Mammalian target of rapamycin (mTOR) inhibitors. The Report gives insights on 20+ products, 18+ companies that are active in this field and 5 different technologies used in the pipeline. This report also provides information on the therapeutic development based on the mTOR inhibitors dealing with all the pipeline drugs, comparative analysis mTOR inhibitors at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. It covers 5+ therapy areas that are being targeted by mTOR inhibitors. The report also covers the company’s information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. This Report will help you to identify emerging players with potentially strong product information, licensing opportunities and helps you to create effective counter-strategies to gain competitive advantage.
Please note: Certain sections in the report may be removed or altered based on the availability and relevance of data. Report Highlights: The new report, provides a Mammalian Target of Rapamycin (Mtor) Inhibitors Landscape across the globe. The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information. Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages. Coverage of the Mammalian Target of Rapamycin (Mtor) Inhibitors based pipeline on the basis of target, MOA, route of administration, technology involved and molecule type. The report reviews key players involved in the therapeutics development for Mammalian Target of Rapamycin (Mtor) Inhibitors and also provide company profiling. Pipeline products coverage based on various stages of development from NDA filings to discovery. Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.